L7 informatics, a leader in data intelligence for scientific and healthcare companies, and Triumvira Immunologics (“Triumvira”) on May 31st, 2022, announced an agreement to implement L7|ESP to enhance the digitalization of its manufacturing of next-generation cell therapies. Triumvira is a clinical-stage company that develops novel, targeted autologous, and allogeneic T cell therapeutics that co-opt the natural biology of T-cells to treat patients with solid tumors. 

With the help of L7, these next-generation cell therapies will allow Triumvira to drive early integration of automation to support its manufacturing scalability with a lower cost of goods, improved reproducibility and consistency, instead of using a siloed and costly point solution approach. L7|ESP will also enable proactive data management and remote monitoring.

Donna Rill, Chief Technology Officer of Triumvira, explained, “With early incorporation of scalable automation, we can facilitate the availability of treatment to patients and decrease the time to market. Having a unified platform like L7|ESP, we can avoid having to implement several separate point solutions, which in turn saves us valuable time and energy.” She continued by saying, “In addition to being the first company in the U.S. to dose a patient with a therapy manufactured with Lonza’s Cocoon® platform, this new agreement is part of our broader strategy to address challenges in manufacturing autologous cell therapies for patients by being at the forefront of innovation.”

Vasu Rangadass, PhD, President and CEO of L7 Informatics, said, “Triumvira completely understands the power of integration of digital automation and the need for a single data fabric to support a successful path to commercialization. This requires an integrated system approach like L7|ESP which offers robust flexibility and power. L7 enables you to start small and scale quickly from research to commercialization.”

L7|ESP is a unified and composable platform with a single data fabric that reduces the total cost of operations while also enabling the digital transformation of biologics operations, including research, clinical operations, process development, manufacturing and quality control. The platform is compliant with the U.S. Food and Drug Administration and comes with several pre-built, best-in-class applications.

Featured Image: Megapixl © Catalin52